Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients

PHASE4CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

January 7, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

October 31, 2023

Conditions
Severe PneumoniaCommunity-acquired PneumoniaHospital-acquired PneumoniaCritical Illness
Interventions
DRUG

Ambroxol Hydrochloride

IV ambroxol hydrochloride 30mg TDS as adjunct therapy to standard therapy for severe pneumonia in ICU for 14 days. Each dose of 30mg of ambroxol will be diluted in 50ml of NS/D5% to be given intravenously over an hour.

OTHER

Standard Therapy

Standard therapy for severe pneumonia as per recommended in the ICU Management Protocols by Malaysian Society of Intensive Care (MSIC). This includes antibiotics stewardship and supportive therapy.

Trial Locations (1)

56000

Hospital Canselor Tuanku Muhriz UKM (HCTM), Cheras

All Listed Sponsors
lead

National University of Malaysia

OTHER